1. New Zealand Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Fisher & Paykel Healthcare Corporation Limited

Fisher & Paykel Healthcare Corporation Limited

FPH.AX
Fisher & Paykel Healthcare Corporation LimitedAU flagAustralian Securities Exchange
33.56
AUD
+0.56
- -
19.71BMarket Cap
Fisher & Paykel Healthcare Corporation Limited
FPH.AX
(Australian Securities Exchange)

Recent

price

33.56

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
FRC
0.9
0.89
0.94
1.04
1.16
1.46
1.54
1.69
1.87
2.22
3.38
2.85
2.75
3.02
2.19
3.93
Revenue per Share
0.1
0.12
0.14
0.18
0.2
0.26
0.3
0.33
0.37
0.5
0.91
0.65
0.43
0.23
0.64
0.8
Basic EPS, GAAP
0.02
0.01
0.01
0.12
0.16
0.11
0.2
-0.17
-0.23
-0.3
-0.32
-0.29
-0.37
-0.58
-0.18
-0.33
Free Cash Flow per Basic Share
0.13
0.13
0.13
0.13
0.09
0.12
0.16
0.18
0.2
0.25
0.31
0.39
0.34
0.25
0.33
0.43
Dividend per Share
0.43
0.47
0.53
0.63
0.74
0.88
1.01
1.17
1.34
1.59
2.22
2.5
2.6
2.58
2.9
3.3
Book Value per Share
0.6
0.65
0.68
0.72
0.81
0.9
1.09
1.25
1.49
1.57
2.5
2.76
2.88
2.87
3.09
3.48
Tangible Book Value per Share
517
526
538
547
556
561
566
570
573
574
576
577
578
582
586
587
Basic Weighted Avg Shares
468
467
507
569
644
818
870
964
1,072
1,273
1,948
1,642
1,589
1,758
1,280
2,308
Sales/Revenue/Turnover
7.71
3.83
6.89
9.68
16.32
21.24
19.68
21.14
23.09
25.76
31.02
22.55
15.15
14.47
-28.98
20.7
Operating Margin (%)
22
23
26
30
32
35
39
45
42
61
85
96
99
114
140
159
Depreciation Expense
52
64
77
97
113
143
169
190
209
287
524
377
250
133
377
468
Net Income, GAAP
43.47
30.55
29.56
28.98
28.72
28.58
29.06
28.98
28.16
22.46
27.01
25.25
23.69
43.74
25.05
25.81
Effective Tax Rate (%)
11.22
13.74
15.19
17.07
17.57
17.52
19.45
19.72
19.51
22.56
26.91
22.95
15.76
7.54
29.46
20.3
Profit Margin (%)
102
44
124
106
126
136
204
246
271
184
492
584
484
320
435
654
Working Capital
82
35
117
64
51
47
40
52
69
44
92
87
124
93
67
113
LT Debt
313
348
372
406
471
542
662
761
913
974
1,521
1,680
1,753
1,759
1,890
2,115
Total Equity
5.08
2.81
5.03
7.57
13.96
21.14
17.84
18.07
18.83
23.45
30.06
15.36
9.87
7.39
-13.61
15.89
Return on Invested Capital (%)
18.05
19.61
20.57
23.45
26.03
29.22
28.89
27.91
26.53
30.52
43.18
25.86
15.98
8.56
21.8
24.23
Return on Capital (%)
24.26
27.24
28.88
30.76
29.88
31.74
31.8
30.71
29.18
34.2
47.87
27.71
16.99
8.83
23.62
25.81
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.45%
6.9%
11.9%
Free Cash Flow
5.78%
19.34%
89.51%
Net Income, GAAP
26.01%
19.99%
24.2%
Sales/Revenue/Turnover
14.49%
8.96%
80.3%
Total Cash Common Dividend
15.8%
9.77%
28.79%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1,758
2025
1,280
- -
- -
- -
1,280
2026
- -
- -
- -
- -
2,308

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.23
2025
0.64
- -
- -
- -
0.64
2026
- -
- -
- -
- -
0.8

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.25
2025
0.33
- -
- -
- -
0.33
2026
- -
- -
- -
- -
0.43
Similar Companies
Innovative Eyewear, Inc. (LUCYW)
Fielmann AG (FLMNF)
Poly Medicure Limited (POLYMED.BO)
Gerresheimer AG (GXI.SW)
Tetratherix Ltd. (TTX.AX)
HOYA Corporation (HOCPF)
Business
Fisher & Paykel Healthcare Corporation Limited designs, manufactures, and markets advanced medical devices and systems primarily for respiratory care, acute care surgery, and the treatment of obstructive sleep apnea. Its core product portfolio includes respiratory humidifiers, breathing circuits, oxygen therapy devices, continuous positive airway pressure (CPAP) systems, neonatal care products such as infant warmers and resuscitators, surgical humidification devices, and related consumables and accessories. The company operates primarily in hospital and homecare markets, serving healthcare providers globally with manufacturing facilities in New Zealand and Mexico and distribution across North America, Europe, and the Asia Pacific. Founded in 1934 and headquartered in Auckland, New Zealand, Fisher & Paykel Healthcare maintains a commitment to clinical innovation and "Care by Design" philosophy to enhance patient outcomes. Recent major developments include the launch in 2024 of the F&P Nova Micro nasal pillows mask for obstructive sleep apnea treatment in the United States and the F&P Solo mask introduction in Australia and New Zealand. The company continues its expansion through new product development, exemplified by robust investment in research and development (NZ$198 million in FY24), and infrastructure growing with a third manufacturing plant opening in Tijuana, Mexico, and plans for an additional facility in Guangzhou, China, aiming to optimize production costs and meet increasing global demand. Fisher & Paykel Healthcare reported a solid 10 percent revenue growth in FY24 to NZ$1.74 billion and anticipates further revenue growth of 11 percent in FY25 driven by hospital product demand and new mask product launches, with projected net profits rising 30 percent. The company’s customer base is predominantly hospitals (62 percent of revenue), supplemented by homecare users, with significant geographic revenue contributions from North America (46 percent), Europe (27 percent), and Asia Pacific (21 percent).